Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents

被引：15
|
作者：
Liu, Shangde [1 ]
Li, Shanshan [1 ]
Yuan, Duo [1 ]
Wang, Enmao [1 ]
Xie, Roujie [1 ]
Zhang, Weiqi [1 ]
Kong, Yi [2 ]
Zhu, Xiong [1 ]
机构：
[1] China Pharmaceut Univ, Inst Med & Chem, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Sch Life & Technol, Nanjing 210009, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 209卷
关键词：
PAR4; Small-molecule antagonists; Antiplatelet agents; SAR; Structural optimization; BMS-986120; BMS-986141; Preclinical trials; Clinical trials; ACUTE CORONARY SYNDROMES; THROMBIN-RECEPTOR; PLATELET ACTIVATION; THROMBOXANE PRODUCTION; IN-VITRO; INHIBITION; YD-3; AGGREGATION; DISCOVERY; PEPTIDES;
D O I：
10.1016/j.ejmech.2020.112893
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Protease activated receptor 4 (PAR4) is a key target in antiplatelet medication to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth while retaining initial thrombus formation by acting on the late diffusion stage of platelet activation, which may provide a safer alternative than other antiplatelet agents. Currently, research on PAR4 antagonists is of increasing interest in the field of antiplatelet agents. This article provides an overview of the discovery and development of small-molecule antagonists of PAR4 as novel antiplatelet agents, including structure-activity relationship (SAR) analysis, progress of structure and bioassay optimization, and the latest structural and/or clinical information of representative small-molecule antagonists of PAR4. (c) 2020 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数：15
相关论文
共 50 条
  • [21] Proteinase activated receptor 4 (PAR4) involvement in the generation of joint pain
    McDougall, J. J.
    Tchitchkan, D.
    Joubert, E.
    Cellars, L.
    Vergnolle, N.
    NEUROPEPTIDES, 2008, 42 (04) : 472 - 472
  • [22] Protease-Activated Receptor-4 (PAR4) Inhibits Pro-Nociceptive Signals and Visceral Hypersensitivity
    Auge, Celine
    Cenac, Nicolas
    Balz-Hara, Daniela
    Vergnolle, Nathalie
    GASTROENTEROLOGY, 2009, 136 (05) : A722 - A722
  • [23] Expression and Purification of Protease-Activated Receptor 4 (PAR4) and Analysis with Histidine Hydrogen-Deuterium Exchange
    de la Fuente, Maria
    Han, Xu
    Miyagi, Masaru
    Nieman, Marvin T.
    BIOCHEMISTRY, 2020, 59 (05) : 671 - 681
  • [24] Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding
    Wong, Pancras C.
    Seiffert, Dietmar
    Bird, J. Eileen
    Watson, Carol A.
    Bostwick, Jeffrey S.
    Giancarli, Mary
    Allegretto, Nick
    Hua, Ji
    Harden, David
    Guay, Jocelyne
    Callejo, Mario
    Miller, Michael M.
    Lawrence, R. Michael
    Banville, Jacques
    Guy, Julia
    Maxwell, Brad D.
    Priestley, E. Scott
    Marinier, Anne
    Wexler, Ruth R.
    Bouvier, Michel
    Gordon, David A.
    Schumacher, William A.
    Yang, Jing
    SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (371)
  • [25] Molecular cloning of the rat proteinase-activated receptor 4 (PAR4)
    Hoogerwerf, WA
    Hellmich, HL
    Micci, MA
    Winston, JH
    Zou, L
    Pasricha, PJ
    BMC MOLECULAR BIOLOGY, 2002, 3
  • [26] A Hypo-reactive Protease Activated Receptor 4 (PAR4) Variant is Associated With a Reduced Risk of Venous Thromboembolism
    Han, Xu
    Knauss, Elizabeth
    Nayak, Lalitha
    Nieman, Marvin T.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2020, 40
  • [27] Protease-activated receptors: PAR4 and counting: how long is the course?
    Hollenberg, MD
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (07) : 271 - 273
  • [28] Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog
    Lin, Yu-Chuan
    Ko, Yen-Chun
    Hung, Shang-Cheng
    Lin, Ying-Ting
    Lee, Jia-Hau
    Tsai, Ju-Ying
    Kung, Po-Hsiung
    Tsai, Meng-Chun
    Chen, Yih-Fung
    Wu, Chin-Chung
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (04) : 694 - 703
  • [29] Discovery of 2,3-Dihydro[1,4]dioxino[2,3-g]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) Antagonists with Potent Antiplatelet Aggregation Activity and Low Bleeding Tendency
    Chen, Panpan
    Chen, Cai
    Zheng, Yizheng
    Chen, Fangjun
    Liu, Zhaojun
    Ren, Shenhong
    Song, Hangyu
    Liu, Tongdan
    Lu, Zhipeng
    Sun, Hongbin
    Kong, Yi
    Yuan, Haoliang
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (07) : 5502 - 5537
  • [30] Elevated protease-activated receptor 4 (PAR4) gene expression in Alzheimer's disease predicts cognitive decline
    Winfree, Rebecca L.
    Erreger, Kevin
    Phillips, Jared
    Seto, Mabel
    Wang, Yanling
    Schneider, Julie A.
    Bennett, David A.
    Schrag, Matthew S.
    Hohman, Timothy J.
    Hamm, Heidi E.
    NEUROBIOLOGY OF AGING, 2024, 140 : 93 - 101
12345